{"id":"NCT01781468","sponsor":"Alliance for Clinical Trials in Oncology","briefTitle":"Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma","officialTitle":"A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (NuvigilÂ®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-06-21","primaryCompletion":"2019-05","completion":"2019-12-15","firstPosted":"2013-02-01","resultsPosted":"2020-05-07","lastUpdate":"2025-01-27"},"enrollment":328,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"SUPPORTIVE_CARE"},"conditions":["Fatigue"],"interventions":[{"type":"DRUG","name":"armodafinil 150 mg","otherNames":[]},{"type":"OTHER","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"armodafinil 250 mg","otherNames":[]}],"arms":[{"label":"Arm I","type":"EXPERIMENTAL"},{"label":"Arm II","type":"PLACEBO_COMPARATOR"},{"label":"Arm III","type":"EXPERIMENTAL"}],"summary":"This randomized phase III trial studies armodafinil to see how well it works in reducing cancer-related fatigue in patients with high grade glioma. Armodafinil may help relieve fatigue in patients with high grade glioma.","primaryOutcome":{"measure":"The Number of Participants With a Response in Terms of a Clinically Meaningful Improvement in Patient-reported Fatigue at 8 Weeks.","timeFrame":"At 8 weeks","effectByArm":[{"arm":"Arm I (150 mg Armodafinil)","deltaMin":29,"sd":null},{"arm":"Arm II (250 mg Armodafinil)","deltaMin":27,"sd":null},{"arm":"Arm III (Placebo)","deltaMin":29,"sd":null}],"pValues":[{"comp":"OG000 vs OG001 vs OG002","p":"0.9601"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":null},"locations":{"siteCount":365,"countries":["United States"]},"refs":{"pmids":["34882169"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":109},"commonTop":["Headache","Fatigue","Nausea","Insomnia","Dizziness"]}}